featured
Lenalidomide Maintenance After Autologous HSCT in Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lenalidomide Maintenance After Autologous Haematopoietic Stem-Cell Transplantation in Mantle Cell Lymphoma: Results of a Fondazione Italiana Linfomi (FIL) Multicentre, Randomised, Phase 3 Trial
Lancet Haematol 2021 Jan 01;8(1)e34-e44, M Ladetto, S Cortelazzo, S Ferrero, A Evangelista, M Mian, R Tavarozzi, M Zanni, F Cavallo, A Di Rocco, V Stefoni, C Pagani, A Re, A Chiappella, M Balzarotti, VR Zilioli, M Gomes da Silva, L Arcaini, AL Molinari, F Ballerini, AJM Ferreri, B Puccini, F Benedetti, PM Stefani, F Narni, I Casaroli, C Stelitano, G Ciccone, U Vitolo, M MartelliFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.